Understanding the levels of specific biomarkers and proteins is critical for preclinical and clinical assessments. These measurements are crucial for all types of research, such as profiling cytokine levels or ADA immunogenicity testing. The Meso Scale Discovery platform is a robust tool for detecting and quantifying biomarkers in complex study matrices. Mesoscale ELISA can assess a broad range of biomarkers with high consistency and low sample volume requirements. This feature makes MSD assays an ideal platform for high-throughput biomarker studies. However, similar to LC-MS/MS method validation, MSD ELISA assays require robust optimization and validation initiatives. The current article dives deep into MSD assay technology for biomarker studies.
Meso Scale Discovery multiplex assays for biomarker discovery
MSD assay employs electrochemiluminescence detection to detect biomarkers in singleplex and multiplex formats. It combines next-generation electrochemiluminescence with multiarray technology to deliver rapid and high throughput data through organization and parallel processing of study samples. MSD products include several assay kits for evaluating biomarkers, cell signaling proteins, and other molecules as well as a wide range of reagents and plates for assay development.Â
MSD is a robust platform for detecting and quantifying biomarkers in biological samples. They have over 400 assay kits and customization capacities to help scientists make precise and accurate determinations of different phosphoproteins, cytokines, and other biomarkers in complex study matrices. Besides, MSD platforms are known for low-cost analysis and minimal effort. Hence, MSD assays are adopted by major biotech companies, clinical research organizations, pharmaceutical companies, and government and academic institutions.
Clinical samples are inherently complex. Hence, evaluating them with traditional methods is challenging. Besides, complex matrices such as vaginal fluids and sputum, limited sample volumes, and wide concentration ranges make these assessments even more difficult. MSD assays overcome all these limitations by offering improved sensitivity, multiplex capacities, a broader dynamic range, and assessments in complex study samples. Moreover, MSD platforms are ideal for regulated workflows as they are available in IQ/OQ/PQ validation packages and with software for 21 CFR Part 11 and GLP compliance.Â
MSD’s broader dynamic range enables scientists to measure biomarkers in diseased and control samples without multiple dilutions. Besides, highly adaptable workflows allow the estimation of biomarkers in complex study matrices. Furthermore, multiplexing capacities and high sensitivity allow the evaluation of several biomarkers in a single reaction volume.
MSD offers support and services at every stage of drug discovery and development. For a special combination of analytes, they deliver a multiplex MSD panel to meet all research and experimental needs. They offer custom panel development by preparing assay kits according to customer preferences along with a working protocol for the assay kit. Besides, their field scientists and support team are in constant touch to support all technical and scientific requirements.
Importantly, if customers cannot find their assay in MSD’s extensive assay list, they can tell their antibody pairs, and MSD will coat those antibodies through their Prototype printing services. They have to identify their analytes of interest, screen the extensive list of MSD assays, select analytes, and contact customer service to order their custom multiplex MSD assay.
